Panacea Biotec Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 1,152 million compared to INR 1,558.8 million a year ago. Revenue was INR 1,291.4 million compared to INR 1,575.4 million a year ago. Net income was INR 193.7 million compared to net loss of INR 492 million a year ago. Basic earnings per share from continuing operations was INR 3.16 compared to basic loss per share from continuing operations of INR 8.03 a year ago.
For the nine months, sales was INR 3,310.2 million compared to INR 5,205 million a year ago. Revenue was INR 3,676.2 million compared to INR 5,274.2 million a year ago. Net loss was INR 210.7 million compared to INR 1,595.6 million a year ago. Basic loss per share from continuing operations was INR 3.44 compared to INR 26.05 a year ago.